LENZ Therapeutics, Inc. (NASDAQ:LENZ) receives an average target price of $35.40 from brokerages

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Your Free Report ) has earned an average recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $35.40.

A number of equities analysts have recently issued reports on LENZ shares. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Raymond James began coverage on LENZ Therapeutics in a report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective for the company. HC Wainwright began coverage on LENZ Therapeutics in a report on Monday, August 12th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th.

Get the latest stock report on LENZ

Institutional inputs and outputs

Several institutional investors have recently made changes to their positions in LENZ. American International Group Inc. bought a new position in LENZ Therapeutics in the first quarter valued at about $44,000. SG Americas Securities LLC bought a new stake in shares of LENZ Therapeutics in the third quarter valued at $107,000. Marquette Asset Management LLC bought a new stake in shares of LENZ Therapeutics in the 1st quarter worth $131,000. Squarepoint Ops LLC bought a new stake in shares of LENZ Therapeutics in the second quarter valued at $181,000. Finally, Rhumbline Advisers boosted its holdings in shares of LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after buying an additional 12,214 shares in the last quarter. Institutional investors own 54.32% of the company’s shares.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ opened at $22.48 on Tuesday. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The company’s fifty-day moving average is $22.88.

LENZ Therapeutics (NASDAQ:LENZ – Get Your Free Report ) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. research analysts forecast that LENZ Therapeutics will post -2.81 earnings per share for the current year.

About LENZ Therapeutics

(Get a free report

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of vision improvement therapies in the United States. Its product candidates include LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Further reading

Get news and reviews for LENZ Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LENZ Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.